Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years

Rosário, Pedro Weslley

doi:10.1590/s0004-27302008000900007

Cited by 22 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, small studies of have found either no change (Foldes et al 1993, Gurlek & Gedik 1999, Ugur-Altun et al 2003, Lee et al 2006 or a small reduction in BMD (Tauchmanova et al 2004, Rosario 2008 in pre-menopausal women with subclinical hyperthyroidism. By contrast, the majority of studies in postmenopausal women demonstrated a reduction in BMD (Foldes et al 1993, Mudde et al 1994, Tauchmanova et al 2004, Lee et al 2006, Belaya et al 2007, Rosario 2008.…”

Section: Endogenous Subclinical Hyperthyroidismmentioning

confidence: 99%

“…Small studies of patients with subclinical hyperthyroidism have reported conflicting results either describing normal (De Menis et al 1992, Faber et al 1994, Mudde et al 1994, Gurlek and Gedik 1999, Lee et al 2006 or elevated (Campbell et al 1996, Kumeda et al 2000, Tauchmanova et al 2004, Belaya et al 2007, Rosario 2008) bone turnover makers. Similarly, small studies of have found either no change (Foldes et al 1993, Gurlek & Gedik 1999, Ugur-Altun et al 2003, Lee et al 2006 or a small reduction in BMD (Tauchmanova et al 2004, Rosario 2008 in pre-menopausal women with subclinical hyperthyroidism. By contrast, the majority of studies in postmenopausal women demonstrated a reduction in BMD (Foldes et al 1993, Mudde et al 1994, Tauchmanova et al 2004, Lee et al 2006, Belaya et al 2007, Rosario 2008.…”

Section: Endogenous Subclinical Hyperthyroidismmentioning

confidence: 99%

See 1 more Smart Citation

The skeletal consequences of thyrotoxicosis

Nicholls¹,

Brassill²,

Williams³

et al. 2012

Journal of Endocrinology

107

View full text Add to dashboard Cite

Euthyroid status is essential for normal skeletal development and the maintenance of adult bone structure and strength. Established thyrotoxicosis has long been recognised as a cause of high bone turnover osteoporosis and fracture but more recent studies have suggested that subclinical hyperthyroidism and long-term suppressive doses of thyroxine (T 4 ) may also result in decreased bone mineral density (BMD) and an increased risk of fragility fracture, particularly in postmenopausal women. Furthermore, large population studies of euthyroid individuals have demonstrated that a hypothalamicpituitary-thyroid axis set point at the upper end of the normal reference range is associated with reduced BMD and increased fracture susceptibility. Despite these findings, the cellular and molecular mechanisms of thyroid hormone action in bone remain controversial and incompletely understood. In this review, we discuss the role of thyroid hormones in bone and the skeletal consequences of hyperthyroidism.

show abstract

Section: Endogenous Subclinical Hyperthyroidismmentioning

confidence: 99%

Section: Endogenous Subclinical Hyperthyroidismmentioning

confidence: 99%

The skeletal consequences of thyrotoxicosis

Nicholls¹,

Brassill²,

Williams³

et al. 2012

Journal of Endocrinology

107

View full text Add to dashboard Cite

show abstract

“…Subclinical thyrotoxicosis is associated with bone mass compromise, especially among postmenopausal women (57,58,133), and morphological and functional heart disorders (57,58), which have more clinical repercussions among older adults. To minimize the adverse effects of suppressive therapy with T4, some steps are important.…”

Section: What Is the Indicated Tsh Level Following Initial Treatment?mentioning

confidence: 99%

Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus

Rosário

Ward

Carvalho

et al. 2013

Arq Bras Endocrinol Metab

123

147

View full text Add to dashboard Cite

Thyroid nodules are frequent findings, especially when sensitive imaging methods are used. Although thyroid cancer is relatively rare, its incidence is increasing, particularly in terms of small tumors, which have an uncertain clinical relevance. Most patients with differentiated thyroid cancer exhibit satisfactory clinical outcomes when treatment is appropriate, and their mortality rate is similar to that of the overall population. However, relapse occurs in a considerable fraction of these patients, and some patients stop responding to conventional treatment and eventually die from their disease. Therefore, the challenge is how to identify the individuals who require more aggressive disease management while sparing the majority of patients from unnecessary treatments and procedures. We have updated the Brazilian Consensus that was published in 2007, emphasizing the diagnostic and therapeutic advances that the participants, representing several Brazilian university centers, consider most relevant in clinical practice. The formulation of the present guidelines was based on the participants' experience and a review of the relevant literature. Arq Bras Endocrinol Metab. 2013;57(4):240-64 Keywords Thyroid nodules; thyroid cancer; Brazilian consensus; update RESUMO Nódulos tireoidianos são muito frequentes, sobretudo quando se empregam métodos sensí-veis de imagem. Embora o câncer seja proporcionalmente raro, sua incidência vem aumentando, especialmente de tumores pequenos, cuja evolução clínica é incerta. A maioria dos pacientes com carcinoma diferenciado de tireoide evolui bem quando adequadamente tratada, com índices de mortalidade similares à população geral. Por outro lado, um percentual não desprezível apresenta recidivas e alguns eventualmente não respondem às terapias convencionais, evoluindo para óbito. Assim, o desafio é distinguir os pacientes merecedores de condutas mais agressivas e, ao mesmo tempo e não menos importante, poupar a maioria de tratamentos e procedimentos desnecessários. Atualizamos o Consenso Brasileiro publicado em 2007, ressaltando os avanços diagnósticos e terapêuticos que os participantes, de diferentes Centros Universitários do Brasil, consideram mais relevantes para prática clínica. A elaboração dessas diretrizes foi baseada na experiência dos participantes e revisão da literatura pertinente. Arq Bras Endocrinol Metab. 2013;57(4):240-64 Descritores

show abstract

“…One of the repercussions of SCH is a decline of bone mineral density (BMD), notably in postmenopausal women and in patients with TSH ≤ 0.1 mIU/L (1,6). However, few studies have evaluated the effect of treatment of SCH on bone metabolism and bone mass (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism

Rosário¹

2013

Arq Bras Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to nonvoluminous nodular goiter and its effect on bone metabolism I therapy in elderly patients with subclinical hyperthyroidism (SCH) due to nodular disease and who did not receive antithyroid drugs (ATDs), and the effect of the treatment on bone metabolism. Subjects and methods: Thirty-six patients with TSH ≤ 0.1 mIU/L and non-voluminous goiter (< 60 cm 3 ) were studied. Bone mineral density (BMD) was assessed in 17 women with osteopenia. Results: Mean 24-h 131 I uptake was 17.5%. Symptoms of thyrotoxicosis were reported by two (5.5%) patients in the first week after therapy. One year after radioiodine treatment, SCH was resolved in 30 (83.3%) patients, and hypothyroidism was detected in one (2.7%). In the patients in whom TSH returned to normal, femoral and lumbar spine BMD increased by 1.9% and 1.6%, respectively, in average. I em 24 h foi 17,5%. Sintomas de tireotoxicose foram reportados por dois pacientes (5,5%) na primeira semana após a terapia. Um ano após o radioiodo, HSC foi resolvido em 30 pacientes (83,3%) e hipotireoidismo ocorreu em 1 (2,7%). Nas pacientes que normalizaram o TSH, DMO em fêmur e coluna lombar incrementou em média 1,9% e 1,6%, respectivamente. Conclusões: Em idosos com HSC e bócio não volumoso, radioiodo, não precedido de DATs, é uma alternativa terapêutica segura e eficaz. Resolução do HSC tem benefício na DMO em mulheres menopausadas com osteopenia. Arq Bras Endocrinol Metab. 2013;57(2):144-7 Descritores Hipertireoidismo subclínico; radioiodo; doença nodular

show abstract

Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years

Cited by 22 publications

References 9 publications

The skeletal consequences of thyrotoxicosis

The skeletal consequences of thyrotoxicosis

Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus

Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism

Contact Info

Product

Resources

About